Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$2.16
-0.7%
$1.64
$0.73
$3.90
$136.39M0.7410,652 shs239,497 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$1.22
-2.0%
$1.19
$0.89
$25.00
$5.32M2.16332,618 shs639,512 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs300 shs
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$7.00
$7.10
$4.07
$7.70
$294.54M0.99133,095 shs12,421 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$4.76
+0.5%
$4.69
$2.10
$6.07
$743.59M0.662.04 million shs1.08 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
0.00%-7.51%+63.26%+62.64%+4.61%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.00%+19.12%-2.02%-10.00%-95.08%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%0.00%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00%0.00%0.00%0.00%0.00%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
0.00%+1.17%+3.82%+7.82%+125.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
1.6402 of 5 stars
3.50.00.00.02.81.70.0
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1.0167 of 5 stars
0.05.00.00.02.40.00.6
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3.6202 of 5 stars
3.41.00.04.20.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
3.00
Buy$6.00178.42% Upside
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.00
N/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00
N/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.83
Moderate Buy$6.2531.44% Upside

Current Analyst Ratings Breakdown

Latest XERS, OBSV, MBIO, GALT, and TLC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/9/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.68) per shareN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A($2.11) per shareN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$3.63M81.14N/AN/A$0.83 per share8.43
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$203.07M3.66N/AN/A($0.20) per share-23.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$54.84M-$0.30N/AN/AN/A-20.25%N/A-12.07%8/6/2025 (Estimated)

Latest XERS, OBSV, MBIO, GALT, and TLC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.20-$0.15+$0.05-$0.15N/AN/A
5/14/2025Q1 2025
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A-$0.05N/A-$0.05N/AN/A
5/8/2025Q1 2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
0.08
0.08
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
1.34
1.34
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.67
3.01
3.01
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.72
1.17

Institutional Ownership

CompanyInstitutional Ownership
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
9.95%
ObsEva SA stock logo
OBSV
ObsEva
17.52%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.22%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
50.10%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.21%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
963.29 million31.58 millionOptionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1004.38 million4.37 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
2,02042.08 millionN/ANot Optionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290156.38 million149.25 millionOptionable

Recent News About These Companies

Xeris Announces Details for Analyst & Investor Day

New MarketBeat Followers Over Time

Media Sentiment Over Time

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$2.15 -0.02 (-0.69%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$2.17 +0.02 (+0.70%)
As of 04:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Mustang Bio stock logo

Mustang Bio NASDAQ:MBIO

$1.22 -0.03 (-2.02%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$1.18 -0.04 (-2.88%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Taiwan Liposome stock logo

Taiwan Liposome NASDAQ:TLC

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$4.76 +0.03 (+0.53%)
Closing price 07/3/2025 02:59 PM Eastern
Extended Trading
$4.76 0.00 (0.00%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.